Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07454382) titled 'A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma' on March 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Memorial Sloan Kettering Cancer Center
Condition:
Multiple Myeloma
Intervention:
Biological: Elranatamab-bcmm
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: February 27, 2026
Target Sample Size: 26
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07454382
Published by ...